Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

http://www.wikidata.org/entity/Q37587057

about

Application of microRNA in diagnosis and treatment of ovarian cancer Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities The quest for an effective and safe personalized cell therapy using epigenetic tools Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.Inhibition of autophagy enhances the anticancer activity of bortezomib in B-cell acute lymphoblastic leukemia cells.DNA methyltransferase inhibitors: an updated patent review (2012-2015).The role of the proteasome in AML.An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.(Immuno)proteasomes as therapeutic target in acute leukemia.

P2860

Q26991620-003ED613-831A-4741-8F7B-5C4CE467A949 Q26995561-39335C6A-96A1-4F63-8A4D-07B019055246 Q28071384-596A09AB-1B2B-458C-B94C-19897C1C8AEC Q28079389-24E8CDFE-C7F6-4D4D-884C-02C21CC2A428 Q33828073-A7B58774-61E9-438C-9FE8-D45D34771135 Q36522939-2BD3FEA1-98BC-4A8E-BD62-34B72DA7CB8B Q38629837-1900919D-0D04-47A0-8FA8-8791EABCE039 Q38864977-E73A6A02-F0C0-4058-B931-D020BFF81430 Q38875074-51A7D839-D2F2-4F5F-80BC-7FBB933B4B0E Q38885370-B7601B35-D1D1-4F96-AB71-E237B174E007 Q39027087-0F4C2BB3-9751-4799-BB09-F8AA60270E81 Q40261354-01C78A56-8D62-4C53-A8CB-19835EC4E21A Q47131929-5B4E5721-3400-4689-B35C-9CA8B4869641

P2860

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

http://www.wikidata.org/entity/Q37587057

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase I study of azacitidine a ...... actory acute myeloid leukemia.

@en

Phase I study of azacitidine a ...... actory acute myeloid leukemia.

@nl

type

label

Phase I study of azacitidine a ...... actory acute myeloid leukemia.

@en

Phase I study of azacitidine a ...... actory acute myeloid leukemia.

@nl

prefLabel

Phase I study of azacitidine a ...... actory acute myeloid leukemia.

@en

Phase I study of azacitidine a ...... actory acute myeloid leukemia.

@nl

P1433

Q37587057-93A902F3-BFE3-478B-B5C2-B2C62A251B02

P1476

Q37587057-B1C63BD0-FEE8-4E31-BCCD-B6D4AABE9EB6

P2093

Q37587057-29A83061-AF04-4212-8ACE-14D87BBE6F8F

Q37587057-328FD486-C706-42D1-9766-DFC200E94584

Q37587057-51277B38-3F39-465F-BC41-358F8275A27F

Q37587057-55862A9F-94EE-46E9-800E-2753B354462F

Q37587057-683C0F5E-E02A-49C9-B16E-55486715373B

Q37587057-B5FEC688-BFC1-4B04-A967-4DCDBF076716

Q37587057-C2131F28-12C5-4580-94F3-767F464BF698

Q37587057-CAB17FFE-77C5-41F8-913E-5AC99856350E

P2860

Q37587057-17103A27-8915-4CBC-8C8C-FE9557B73D7E

Q37587057-1864900A-8B6A-4FAD-8349-C4550875AE50

Q37587057-2A163953-46D6-4F2D-913C-1549E89E8AFA

Q37587057-426FF207-0BC6-4FB8-9E9C-6D46D261001B

Q37587057-477A73B8-4F53-4C7F-A9B7-708F029120CD

Q37587057-4EDA1D4C-94E2-472B-B899-7E3F85880876

Q37587057-5B9F0FA1-FCA6-45A2-A569-0193BEB65119

Q37587057-604ED33E-5FD9-436A-88E3-611E57CA3F77

Q37587057-67E5240C-6D48-45BD-996E-B0B16828AADA

Q37587057-6DA11FEF-7C6C-4595-8039-09DEC53F1A02

P304

Q37587057-36B2073A-1F4C-4B2F-9959-A9EA4B5B1DAF

P31

Q37587057-F65747D4-8495-40B0-A15A-3292B9AE3942

P356

Q37587057-5F9735C3-947A-4A54-80A8-109BDCA3EC7E

P433

Q37587057-94A99E5F-BC5D-421C-B738-D798FF7C724D

P478

Q37587057-26144A7E-0C3B-40CC-AB20-B597F2450165

P50

Q37587057-0A6564F6-F37A-424D-9AC5-E101080A315C

Q37587057-20993815-56BB-4BCC-8E8A-A2A67A39F73A

Q37587057-4AE267BF-96AF-4EB1-A15B-584659A27834

P577

Q37587057-1C54C72D-7356-4C14-81D4-58609124FB57

P698

Q37587057-94539492-F487-4081-830C-35CC93F12E7D

P921

Q37587057-3932DE11-71A0-4CE7-96F5-A6D5B1618810

P932

Q37587057-E51407EE-6454-4993-9D27-661F6B56AA35

P356

10428194.2013.833333

P1433

Leukemia & Lymphoma

P1476

Phase I study of azacitidine a ...... actory acute myeloid leukemia.

@en

P2093

Alison R Walker

http://www.w3.org/2001/XMLSchema#string

Kristina Humphries

http://www.w3.org/2001/XMLSchema#string

Larry J Schaaf

http://www.w3.org/2001/XMLSchema#string

Michael R Grever

http://www.w3.org/2001/XMLSchema#string

Ramiro Garzon

http://www.w3.org/2001/XMLSchema#string

Rebecca B Klisovic

http://www.w3.org/2001/XMLSchema#string

Steven M Devine

http://www.w3.org/2001/XMLSchema#string

William Blum

http://www.w3.org/2001/XMLSchema#string

P2860

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.

Acute myeloid leukemia.

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

The role of mutations in epigenetic regulators in myeloid malignancies.

P304

1304-1308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2013.833333

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23952243

http://www.w3.org/2001/XMLSchema#string

P921

P932

3925754

http://www.w3.org/2001/XMLSchema#string